Table 2 Drug treatment and morbidity at 6 and 12 months
| Â | Control nA=11 | Intervention nB= 14 | P value (A-B) |
|---|---|---|---|
6 months Use at optimum dose | Â | Â | Â |
ACEi + β blocker | 0 (0%) | 3 (21%) | 0.250 |
ACEi | 3 (27%) | 8 (57%) | 0.414 |
Ramipril | 2 (18%) | 6 (43%) | 0.402 |
β blocker | 2 (18%) | 3 (21%) | 1.000 |
Bisoprolol | 0 (0%) | 3 (21%) | 0.250 |
Spironolactone | 0 (0%) | 0 (0%) | - |
Use at any dose | Â | Â | Â |
ACEi + β blocker | 5 (45%) | 10 (71%) | 0.442 |
ACEi | 5 (45%) | 13 (93%) | 0.075 |
Ramipril | 4 (36%) | 11 (79%) | 0.122 |
β blocker | 7 (64%) | 12 (86%) | 0.653 |
Bisoprolol | 5 (45%) | 11 (79%) | 0.397 |
Spironolactone | 0 (0%) | 2 (14%) | 0.500 |
Morbidity | Â | Â | Â |
Hospitalisations at 6 months for HF | 0 (0%) | 0 (0%) | - |
Hospitalisations at 6 months for CVD | 0 (0%) | 0 (0%) | - |
Hospitalisations at 6 months for any cause | 2 (18%) | 1 (7%) | 0.498 |
12 months (post-trial) | Control n A = 8 | Intervention n B = 13 | P value (A-B) |
Use at optimum dose | Â | Â | Â |
ACEi + β blocker | 0 (0%) | 1 (8%) | 1.000 |
ACEi | 3 (38%) | 5 (38%) | 1.000 |
Ramipril | 3 (38%) | 4 (31%) | 1.000 |
β blocker | 0 (0%) | 1 (8%) | 1.000 |
Bisoprolol | 0 (0%) | 1 (8%) | 1.000 |
Spironolactone | 0 (0%) | 0 (0%) | - |
Use at any dose | Â | Â | Â |
ACEi + β blocker | 5 (63%) | 7 (54%) | 1.000 |
ACEi | 6 (75%) | 11 (85%) | 0.609 |
Ramipril | 5 (63%) | 10 (77%) | 0.376 |
β blocker | 5 (63%) | 7 (54%) | 1.000 |
Bisoprolol | 5 (63%) | 7 (54%) | 1.000 |
Spironolactone | 0 (0%) | 2 (15%) | 0.494 |
Morbidity | Â | Â | Â |
Hospitalisations at 12months for HF | 0 (0%) | 0 (0%) | - |
Hospitalisations at 12 months for CVD | 0 (0%) | 0 (0%) | - |
Hospitalisations at 12 months for any cause | 2 (25%) | 3 (23%) | 1.000 |